

# **Exhibit 34**

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF OHIO  
EASTERN DIVISION

-----X  
**IN RE: NATIONAL PRESCRIPTION** : Case No. 1:17-md-2804  
**OPIATE LITIGATION** : Cleveland, Ohio  
:  
:  
**THIS DOCUMENT RELATES TO:** : Thursday, May 28, 2020  
: 1:03 p.m.  
*County of Summit, Ohio, et al.* :  
*v. Purdue Pharma L.P., et al.,* :  
*Case No. 18-op-45090* :  
:  
:  
*The County of Cuyahoga, Ohio, et* :  
*al. v. Purdue Pharma L.P., et al.,* :  
*Case No. 17-op-45004* :  
:  
:  
*Track 1B Cases* :  
:  
-----X

\*\* SEALED \*\*

TRANSCRIPT OF STATUS CONFERENCE PROCEEDINGS  
BEFORE THE HONORABLE DAN AARON POLSTER  
UNITED STATES DISTRICT JUDGE  
- AND -  
BEFORE THE HONORABLE DAVID A. RUIZ  
UNITED STATES MAGISTRATE JUDGE

SPECIAL MASTER: DAVID R. COHEN

Court Reporter: Donnalee Cotone, RMR, CRR, CRC  
United States District Court  
801 West Superior Avenue  
Court Reporters 7-189  
Cleveland, Ohio 44113  
donnalee\_cotone@ohnd.uscourts.gov

Proceedings recorded by mechanical stenography, transcript  
produced by computer-aided transcription.

1 APPEARANCES (*ALL PARTICIPANTS APPEARING TELEPHONICALLY*):

2

3 On behalf of Plaintiffs:

4

**PETER H. WEINBERGER, ESQ.**  
Spangenberg, Shibley & Liber  
1001 Lakeside Avenue, Suite 1700  
1900 East Ninth Street  
Cleveland, Ohio 44114  
216-696-3232  
pweinberger@spanglaw.com

8

**W. MARK LANIER, ESQ.**  
The Lanier Law Firm  
6810 FM 1960 West  
Houston, Texas 77069  
813-659-5200  
wml@lanierlawfirm.com

9

10

11

12

13

**HUNTER J. SHKOLNIK, ESQ.**  
400 Broadhollow Road, Suite 305  
Melville, New York 11747  
212-397-1000  
hunter@napolilaw.com

14

15

16

17

18

19

20

21

22

23

24

25

1 APPEARANCES (ALL PARTICIPANTS APPEARING TELEPHONICALLY) :

2

3 On behalf of Plaintiffs:

4

**DONALD MIGLIORI, ESQ.**

5

**LINDA SINGER, ESQ.**

6

**JOSEPH F. RICE, ESQ.**

7

Motley Rice LLC

8

28 Bridgeside Boulevard

9

Mount Pleasant, South Carolina 29465

10

843-216-9140

11

dmigliori@motleyrice.com

12

lsinger@motleyrice.com

13

jrice@motleyrice.com

14

15

**PAUL T. FARRELL, JR., ESQ.**

16

Greene, Ketchum, Farrell, Bailey & Tweel LLP

17

419 Eleventh Street

18

Huntington, West Virginia 25701

19

304-525-9115

20

paul@greeneketchum.co

21

22

23

24

25

1 APPEARANCES (ALL PARTICIPANTS APPEARING TELEPHONICALLY) :

2  
3 On behalf of Defendants Walgreen Co. and Walgreen  
4 Eastern Co.:

5 **KASPAR J. STOFFELMAYR, ESQ.**

(CHAIN PHARMACY LIAISON COUNSEL)

- and -

6 **KATHERINE M. SWIFT, ESQ.**

Bartlit Beck LLP

7 54 West Hubbard Street, Suite 300

Chicago, Illinois 60654

8 312-494-4400

kaspar.stoffelmayr@bartlitbeck.com

9 kate.swift@bartlitbeck.com

10  
11 On behalf of Defendants CVS Pharmacy, Inc. and Ohio  
12 CVS, L.L.C. ("CVS"):

13 **ERIC R. DELINSKY, ESQ.**

**SASHA MILLER, ESQ.**

14 **GRAEME W. BUSH, ESQ.**

Zuckerman Spaeder

15 1800 M Street, NW

Washington, DC 20036

202-778-1831

16 edelinsky@zuckerman.com

smiller@zuckerman.com

17 gbush@zuckerman.com

18 On behalf of Defendants HBC Service Company, an  
19 unincorporated operating division of Giant Eagle,  
Inc. ("HBC/Giant Eagle"):

20 **ROBERT M. BARNES, ESQ.**

**JOSH A. KOBRIN, ESQ.**

21 Marcus & Shapira

35th Floor

22 One Oxford Centre

301 Grant Street

23 Pittsburgh, PA 15219

412-471-3490

24 rbarnes@marcus-shapira.com

25 kobrin@marcus-shapira.com

1 APPEARANCES (ALL PARTICIPANTS APPEARING TELEPHONICALLY):

2  
3 On behalf of Defendant Discount Drug Mart, Inc.:

4 **TIMOTHY D. JOHNSON, ESQ.**

Cavitch Familo & Durkin

5 20th Floor

1300 East Ninth Street

6 Cleveland, OH 44114

216-621-7860

7 tjohnson@cavitch.com

8  
9 On behalf of Defendants Rite Aid of Maryland, Inc.  
d/b/a Mid-Atlantic Customer Support Center, Rite Aid  
10 of Ohio, Inc. and Rite Aid Hdqtrs. Corp. ("Rite Aid"):

11 **KELLY A. MOORE ESQ.**

Morgan, Lewis & Bockius

12 101 Park Avenue

New York, NY 10178

13 212-309-6612

kelly.moore@morganlewis.com

14 - and -

15 **JOHN P. LAVELLE, JR., ESQ.**

16 Morgan, Lewis & Bockius LLP

1701 Market St.

17 Philadelphia, PA 19103-2921

215-963-5000

18 john.lavelle@morganlewis.com

19 - and -

20 **GREGORY T. FOUTS, ESQ.**

Morgan, Lewis & Bockius LLP

21 77 West Wacker Dr.

Chicago, IL 60601-5094

22 312-324- 1776

gregory.fouts@morganlewis.com

23

24

25

1 APPEARANCES (*ALL PARTICIPANTS APPEARING TELEPHONICALLY*) :

2

3

On behalf of Defendant Walmart, Inc.:

4

**TINA M. TABACCHI, ESQ.**

5

**TARA A. FUMERTON, ESQ.**

6

**JOHN M. MAJORAS, ESQ.**

Jones Day

7

77 West Wacker

Suite 3500

8

Chicago, Illinois 60601

312-782-3939

9

ttabacchi@jonesday.com

tfumerton@jonesday.com

10

jmajoras@jonesday.com

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 AFTERNOON SESSION, THURSDAY, MAY 28, 2020

2 (Proceedings commenced at 1:03 p.m. p.m.)

3 - - -

4 JUDICIAL ASSISTANT: Before Judge Polster

13:03:53 5 starts, I would like to remind everyone that there is a  
6 court reporter on your line -- on the line.

7 I would ask that you mute your phones if you're not  
8 speaking. I would ask that you identify yourself every  
9 single time you speak.

13:04:09 10 I would also ask that because this is a teleconference  
11 and not an in-person conference, we can lose a little  
12 something in translation. It's very hard for her to hear,  
13 and she works very hard to get everything correctly.

14 So please speak a little slow, speak a little loud,  
13:04:25 15 pronounce your words clearly.

16 Okay. Judge, you're on. Go ahead.

17 THE COURT: All right. Good afternoon,  
18 everyone. This is a status conference in the opioid MDL,  
19 primarily the Track 1B and Track 3.

13:04:45 20 There's sort of a clicking on the background. If  
21 everyone could mute their phones when you're not speaking, I  
22 would appreciate it. I don't know if everyone else is  
23 hearing that.

24 MR. WEINBERGER: Yes, Judge. I think we all  
13:05:03 25 are.



1 THE COURT: There it goes again.

2 Okay. All right. We've been getting filings back and  
3 forth. There's volleys back and forth. And I'm trying to  
4 sort them out, and I want to get both of these cases on  
13:05:32 5 track. One is set for November. One is going to be May  
6 of 2021.

7 I didn't want to have two trials with pharmacies. All  
8 right? That wasn't my intent. My intent was to have one.  
9 It was set for November. It was to cover everything that  
13:05:54 10 pharmacies do. Pharmacies primarily dispense drugs. They  
11 also distribute to themselves, but distribution is to  
12 themselves.

13 So I've been, you know, struggling for two years to  
14 understand how you separate a pharmacy's responsibility as a  
13:06:18 15 distributor from its responsibilities as a dispenser. And  
16 I'm still struggling with it. So I wanted one trial, and  
17 that's why I did what I did, committed the plaintiffs to  
18 amend their complaints to add dispensing claims.

19 The pharmacies filed their mandamus action. The Sixth  
13:06:42 20 Circuit ruled the way they did, so we now have -- we are  
21 where we are.

22 But I'm curious. You know, the pharmacies, in your  
23 filings, you seem to complain that either the plaintiffs are  
24 doing something wrong or the Court is doing something wrong  
13:06:59 25 in creating Track 3 trial.

1 But had you given any thought to what would happen if  
2 you prevailed in your mandamus action what I would do? I'm  
3 just curious.

4 I mean, had you given any thought as to what I was  
13:07:19 5 likely to do?

6 MR. STOFFELMAYR: All right. Judge, it's  
7 Kaspar Stoffelmayr.

8 Maybe I can address that as current liaison counsel.  
9 I don't want to, you know, overstep my bounds speaking on  
13:07:31 10 behalf of anybody. But I think -- I mean the short answer  
11 is yes. The longer answer, you know, probably involves work  
12 product and privilege discussions.

13 But at least to deal to with our --

14 THE COURT: I'm not --

13:07:47 15 MR. STOFFELMAYR: -- with our --

16 THE COURT: I'm not looking to pervade work  
17 product, obviously.

18 MR. STOFFELMAYR: I understand. I wouldn't --  
19 I didn't . . .

13:07:53 20 But I think you know what our position is, and I don't  
21 know that it's useful to reargue it on the phone today.

22 But our position going back many, many months has been  
23 that there is a -- you know, a full slate of bellwether  
24 trials before the federal courts and a lot of cases in front  
13:08:15 25 of state courts as well, including multiple cases involving

1 dispensing claims, and that's where we -- you know, that's  
2 where we believe it would make most sense to focus --

3 THE COURT: Well, I know --

4 MR. STOFFELMAYR: -- our efforts, and --

13:08:27 5 THE COURT: -- I know, Mr. Stoffelmayr, that  
6 has been your position, but what have you -- what have --  
7 you all must have given some thought to what you thought I  
8 would likely do. I'm the MDL judge.

9 Well, you know, I'm not going to waste time on this.  
13:08:46 10 I think if you had all given some -- any thought at all, you  
11 would have guessed that I did what I have done. It's my job  
12 as the MDL judge to do most of the -- most of the MDL work.  
13 That's how it goes.

14 So I'm the one who is supposed to oversee the  
13:09:09 15 discovery, deal with all the motions, get at least one case  
16 ready for trial. If it goes to trial, try it. So that all  
17 of my colleagues around the country, state court, federal  
18 court, don't have to reinvent the wheel. If they want to,  
19 of course, they can. They're not bound to follow any of my  
13:09:32 20 rulings. It's not binding. But typically judges do it.

21 And since, you know, if -- pharmacies should have  
22 figured that if they prevailed in their argument to the  
23 Sixth Circuit that it wasn't proper for the Court to permit  
24 the plaintiffs to add dispensing claims to Track 1B, then I  
13:09:55 25 would just come up with another case in the Northern

1 District of Ohio to include those claims so we could have  
2 the discovery and the motions and a trial, if necessary. So  
3 I would have the first trial.

4 I mean, that's what I did with the manufacturers and  
13:10:12 5 the distributors. We went all the way up to the night  
6 before the trial and then that settled. But that wasn't my  
7 doing. I wasn't involved in that settlement. I was ready  
8 to try the case.

9 So I've done what everyone should have expected me to  
13:10:29 10 do and what I think the MDL court would expect me to do and  
11 that's what I've done.

12 So we now have a trial set for next May with  
13 everything the pharmacies do, distributing and dispensing.

14 And I know everyone is working on the schedule. You  
13:10:50 15 know, I'll go pretty much with whatever schedule you all  
16 come up with so long as it leaves me enough time to address  
17 all the motions, which I'm sure I'll get.

18 One change is the Sixth Circuit conference is in mid  
19 to late June of 2021. It was supposed to be June of this  
13:11:10 20 year, but because of COVID-19, it was cancelled.

21 So I need the trial to start May the 10th, two weeks  
22 before what you proposed, so if you just factor that in.

23 Now, we have the Track 1B, which is dispensing claims  
24 only. And I am still struggling, as I have been for two  
13:11:40 25 years, to figure out how to separate the two halves of what

1 a pharmacy does into an intelligible trial.

2 All right. There's one claim, the public nuisance.

3 And I'm going to go back to Track 3. The idea of Track 3

4 was to recreate what Track 1B was going to be. We just had

13:12:07 5 two different counties. Everything else was going to be the

6 same.

7 So that's why we're only going to try the claim of

8 public nuisance, and as I made clear with Track 1B, there

9 will be no further trial against the pharmacy -- pharmacies

13:12:26 10 in Track 3 of any claim other than public nuisance. That

11 isn't going to happen. So they're going to trial, Lake

12 County, Trumbull County, public nuisance only. All right?

13 So you don't have to worry about the other claims.

14 And all these different entities the plaintiffs have

13:12:46 15 added, my intent was to have the same entities that we had

16 in Track 1B unless some additional entities are needed for

17 the dispensing claims. I'm not quite sure why they would

18 be. And we had -- everyone had agreed that for purposes of

19 trial, everyone could just refer to a corporate entity.

13:13:07 20 So we have six corporate entities; Walmart, Discount

21 Drug Mart, Rite Aid, Giant Eagle, Walgreens, and CVS. With

22 the exception of CVS -- and I understand the statute of

23 limitations argument, and that for one period there was one

24 CVS entity that was a distributor, and then for another

13:13:27 25 period there was another entity. So for CVS we'll have two.

1 But it's my intent that for Track 3, again, we'll just  
2 be referring to Walmart, Rite Aid, Giant Eagle, et cetera.  
3 So the parties are to work that out. I don't -- and the one  
4 name on the jury form, jury verdict forms is for the jury.  
13:13:51 5 So you all can work that out. We're doing it -- basically  
6 it's a re-creation.

7 All right. I'm going to ask some questions. I'm  
8 not -- these aren't rhetorical. I'm really struggling with  
9 the answers.

13:14:09 10 I sent out today the jury instructions, the final jury  
11 instructions that I plan to give. My staff and I have been  
12 working on this for months. We got a lot of comments from  
13 both sides. We have factored those in. My objective was to  
14 craft instructions that are legally correct and readily  
13:14:33 15 understandable for a lay jury, and I think I've got it.

16 Everyone agrees that, you know, the plaintiffs have to  
17 prove that the defendants committed, each of them, some  
18 either intentional conduct or unlawful conduct that caused  
19 the significant interference to the public right to health  
13:15:00 20 or safety. Here's it's the opioid epidemic. All right?

21 But that isn't enough. That isn't enough. There's  
22 also a causation element, and we defined that pretty  
23 clearly, that the plaintiff would have to prove that each of  
24 the defendants, whatever they did or didn't do, was a  
13:15:19 25 substantial factor in creating the public nuisance.

1 Now, am I correct that the public nuisance is the  
2 pills getting out into the community, not just sitting in  
3 the pharmacies, locked up in the pharmacies, but getting out  
4 into the community?

13:15:48 5 And do both sides agree with that?

6 MR. WEINBERGER: On behalf of plaintiff, we  
7 agree. This is Pete Weinberger.

8 THE COURT: Okay. What about the defendant?

9 MR. STOFFELMAYR: Again, Kaspar Stoffelmayr.

13:16:04 10 I think I can say on behalf of everybody, the pills  
11 are not in the community as they're sitting in a locked  
12 cabinet. As far as I can see, nobody would assert that  
13 they're doing any harm to anybody.

14 THE COURT: Okay. Well, that's what I  
13:16:19 15 thought. I mean, but, you know, there's been disagreement  
16 on a whole lot of things.

17 All right. So and, of course, pharmacies, you know,  
18 that's what they do. They dispense drugs. Everyone knows  
19 that. That's where you get your prescriptions filled.

13:16:39 20 The next question is for the plaintiffs. I guess,  
21 Peter, you were responding.

22 It's my understanding that you will -- you are going  
23 to attempt to prove for each of the corporate defendants one  
24 of -- one, two, or three of the following:

13:17:01 25 One, for all or most of the period that the

1 corporation didn't have a SOMS, a suspicious order monitored  
2 system, or two, even if they had one, it wasn't a robust  
3 one, and/or three, even if they had one and it was robust,  
4 they really didn't use it. They had this policy, but they  
13:17:27 5 didn't use it.

6 Am I right that your proof is going to be for each of  
7 the defendants, one, two, and/or three?

8 MR. WEINBERGER: Yes, Your Honor.

9 This is Pete Weinberger again.

13:17:40 10 Yes. The answer is yes.

11 THE COURT: Okay. All right.

12 Now, the next question is: What are your witnesses  
13 going to say that a distributor is legally obligated to do  
14 if they receive a suspicious order from one of their, in  
13:18:10 15 this case, one of their pharmacies? They're distributing to  
16 themselves. All right?

17 So what is a prudent corporate pharmacy supposed to do  
18 if they receive a suspicious order?

19 MR. WEINBERGER: They are to perform due  
13:18:26 20 diligence and --

21 THE COURT: Okay.

22 MR. WEINBERGER: -- I'm happy to expand on  
23 that.

24 THE COURT: Yeah, what -- all right. Yeah.

13:18:33 25 MR. WEINBERGER: Sure.



1 THE COURT: I'd like you to expand on what are  
2 they to do to exhibit or perform due diligence.

3 MR. WEINBERGER: So they are to required to  
4 look at that order and compare it to prior orders that came  
13:18:52 5 from that pharmacy that resulted in distribution of pills to  
6 that pharmacy.

7 They are to look at similar -- similarly situated  
8 pharmacies and determine whether or not the particular order  
9 that is flagged as suspicious meets certain criteria that  
13:19:20 10 the -- that the distribution side should be looking at, and  
11 then they are to utilize information that they have with  
12 respect to the pharmacy's dispensing -- prior dispensing  
13 practices and also current dispensing practices to determine  
14 whether at the store level there is information that  
13:19:57 15 suggests that prescriptions that were dispensed resulted in  
16 or triggered red flags.

17 So it's utilizing the unique position that pharmacies  
18 as distributors are in in that they have knowledge and  
19 control and visibility not only at the distribution level,  
13:20:34 20 but they also have evidence from the pharmacy side in terms  
21 of knowledge, control, and visibility.

22 All of -- and if you combine all of this information,  
23 it is information that they are required to utilize to  
24 discharge their distribution responsibilities under the CSA  
13:21:03 25 1301.74(b).

1 THE COURT: Okay. All right. I think that  
2 was a very clear description.

3 Do the pharmacies agree that that's -- that that's  
4 what they're required to do to exercise due diligence?

13:21:25 5 MR. STOFFELMAYR: Judge, Kaspar Stoffelmayr  
6 again.

7 I don't think anybody would agree with the way  
8 Mr. Weinberger put it, and there's a couple of different  
9 levels of disagreement probably.

13:21:39 10 THE COURT: All right.

11 MR. STOFFELMAYR: One is from the plaintiffs'  
12 perspective, 80 to 90 percent of orders were suspicious.

13 The way it works in the real world, obviously, that's  
14 not the case.

13:21:56 15 THE COURT: Well, all right. I'm not -- I'm  
16 not asking you whether you would agree with whether a given  
17 order is suspicious or not. I'm just -- I asked  
18 Mr. Weinberger to go through the steps of what a pharmacy  
19 should do if they received an order that they deem  
13:22:15 20 suspicious. All right? The steps they should take. And I  
21 want to know if you have -- if you have any serious quarrel  
22 with, All right, this is what we as a prudent pharmacy  
23 should do if we get an order from one of our stores that we  
24 deem suspicious.

13:22:37 25 MR. STOFFELMAYR: Yeah. The answer is going

1 to -- there isn't a one-size-fits-all answer is the -- you  
2 know, the short version.

3 Different chains are going to have done different  
4 things at different points in time, and they were all in the  
13:22:55 5 view -- or certainly in the view of DEA and others, you  
6 know, we were appropriate at the time.

7 In some cases, the required step may be as simple as a  
8 phone call to the pharmacy. In some cases, it may be a  
9 simple glance at the pharmacy's ordering history that shows  
13:23:15 10 you, for example, that they received no shipment the prior  
11 week because it was Independence Day, and so unsurprisingly  
12 they are receiving a -- they have placed a larger order and  
13 they're receiving a larger order.

14 THE COURT: All right. I'm --

13:23:31 15 MR. STOFFELMAYR: This is -- might require --

16 THE COURT: I'm not -- I understand that the  
17 level of inquiry is simply, you know, equivalent to the  
18 suspicion. Okay, obviously. There's a big order, and you  
19 determined they got none the prior week, you're satisfied.

13:23:46 20 But Mr. Weinberger outlined some steps that said at  
21 sometime -- sometimes a corporate pharmacy might need to  
22 look at the dispensing practices of that particular store in  
23 exercising its due diligence. And I'm just asking, does  
24 anyone's pharmacies quarrel with that; that at times your  
13:24:18 25 due diligence could extend to looking at dispensing

1 practices of that pharmacy?

2 MR. STOFFELMAYR: I am aware of no authority  
3 to support that position, that the due diligence for a  
4 suspicious order would require a consideration of dispensing  
13:24:34 5 data, detailed dispensing information at a particular store.

6 Some of the experts talk about a very general  
7 know-your-customer requirement. But the requirements are  
8 exactly the same.

9 COURT REPORTER: Mr. Stoffelmayr.

10 Mr. Stoffelmayr, this is the court reporter.

11 MR. STOFFELMAYR: Yes.

12 COURT REPORTER. Can you -- we're getting some  
13 feedback. Can you please make sure you take it off speaker  
14 or . . .

13:25:03 15 MR. STOFFELMAYR: Let me try something  
16 different. I don't know if this is any better. There was a  
17 headphone involved before.

18 Is this better?

19 COURT REPORTER: Yes.

13:25:16 20 MR. STOFFELMAYR: What I said is, I'm not  
21 aware of any -- there is authority. Some of the experts  
22 talk about a very general idea that you need to know your  
23 customer. And the requirements on a distributor are not  
24 going to -- the requirements for a -- the requirements on a  
13:25:32 25 distributor is to know your customer. That may mean

1 something different if you are a Cardinal or a McKesson  
2 distributing to unaffiliated pharmacies than it does to a  
3 pharmacy inside your own, you know, corporate family  
4 college.

13:25:51 5 But I'm aware of no authority that ever says the  
6 evaluation of a red flag means to pull patient level  
7 dispensing data at the individual source. I've never heard  
8 anyone say that. I've never seen anything that says that.

9 THE COURT: Well, you mean you would  
13:26:10 10 never -- I'm not saying you necessarily would go to the  
11 point of identifying -- of looking at each and every  
12 prescription.

13 But are you saying that your due diligence as a  
14 distributor would never entail checking to see if in a given  
13:26:31 15 month the pharmacy had -- actually had received the -- the  
16 number of prescriptions that would have justified that  
17 order?

18 MR. STOFFELMAYR: Well, if the question is --  
19 if the question is whether the pharmacy actually had  
13:26:55 20 prescriptions, that's different than this -- what I  
21 understood Mr. Weinberger to say. That would be a theft  
22 issue. And there are all sorts of controls, you know,  
23 inventory controls to identify pills that go missing, so to  
24 speak, that are not dispensed to a prescription. I don't  
13:27:16 25 know -- even know if -- again, this might depend by the

1 company at the point in time, but that's not typically  
2 considered a suspicious order monitoring problem; that's a  
3 theft prevention -- a pilferage prevention issue.

4 THE COURT: Could the --

13:27:31 5 MR. STOFFELMAYR: There's all sorts of layers  
6 of control.

7 THE COURT: It could be a lot of things. All  
8 right? Going out the back door, in other words, you know,  
9 as a catchall. Out the front door, you're filling  
13:27:43 10 prescriptions. Out the back door is theft, pilferage, black  
11 market, whatever.

12 MR. STOFFELMAYR: And if the computer system  
13 shows, you know, inventory coming in that's not reflected by  
14 prescriptions being filled, I think just about everywhere,  
13:28:00 15 that is a big issue covered by, you know, asset prescription  
16 and compliance programs. That's not a suspicious order  
17 monitoring function.

18 Although, I suppose if a pharmacy's orders were large  
19 only because the pharmacy technician was a thief and, you  
13:28:21 20 know, stealing large volumes, you know, you could make an  
21 argument if they overlap.

22 But that's not the purpose of this suspicious order  
23 monitoring system. They're not there to address theft.  
24 There are many layers of control to address theft, but  
13:28:33 25 that's a different issue from the regulatory perspective.

1 THE COURT: Well, all right. Maybe I wasn't  
2 aware that you separated the two.

3 But you have to have those -- you have to have those  
4 controls or else you don't have a good -- you don't have a  
13:28:50 5 good system.

6 MR. STOFFELMAYR: The -- and, in fact, the  
7 regulations are -- if you, you know, pull out the  
8 regulations, you know -- is for more attention paid to  
9 physical security measures than this sort of order  
13:29:10 10 monitoring that we're talking about.

11 COURT REPORTER: Can you repeat that,  
12 Mr. Stoffelmayr. There is static coming on --

13 MR. STOFFELMAYR: Certainly.

14 I said the regulations are, in some senses, in some  
13:29:15 15 ways very focused on physical security measures designed to  
16 address exactly this issue, pilferage, whether it is a bad  
17 employee, or somebody who has found a way to break in,  
18 things fall off trucks, whatever it is that can happen out  
19 in the world is, of course, something that is of, you know,  
13:29:36 20 intense interest to the people who own the pills. You know,  
21 obviously it's a loss to the pharmacy and it's of great  
22 interest to law enforcement.

23 THE COURT: Well, what I'm -- what I'm trying  
24 to determine -- you know, I had asked the pharmacies  
13:30:03 25 individually whether they anticipated calling

1 pharmacies -- pharmacists as witnesses, not just someone who  
2 has a pharmacist license, but active pharmacists from their  
3 stores to testify in trial. And several of them said they  
4 would and they outlined the testimony, and candidly, I -- it  
13:30:26 5 looked to me like dispensing testimony, at least in part.

6 And, you know, the pharmacists were very successful in  
7 getting that cut out of the case, and I'm certainly not  
8 going to let it back in.

9 So it seems to me that -- I mean, the plaintiffs'  
13:30:45 10 proof really -- the plaintiffs' proof requires few, if any,  
11 witnesses. It's all documents. And the defendants -- the  
12 defendants should require few, if any, witnesses, just  
13 documents.

14 The issue is, look at the records. Were there  
13:31:02 15 suspicious orders, and if so, what did the defendants do to  
16 show due diligence? And that's what we've got.

17 And so we don't need testimony from -- on the  
18 plaintiffs' side from pharmacists as to what happened in  
19 individual pharmacies and we don't need it from the  
13:31:27 20 defendants either because whatever happened and whatever was  
21 done was done years ago, and it's in the records.

22 So this is a historic case.

23 Now, but the problem -- the problem I'm still  
24 struggling with is, how do the plaintiffs prove and how do  
13:31:52 25 the defendants defend on the causation element without



1 getting into dispensing practices or testimony to the trial  
2 as to how pills got out into the community?

3 Because we agree that there's -- if the pills stay in  
4 the pharmacists [sic], there's no public nuisance. It's  
13:32:21 5 only -- if they get out in the community and people get  
6 addicted and die, and that's the -- that's the health harm,  
7 and the issue is, did anything the pharmacist did or didn't  
8 do substantially cause that?

9 But there's got to be testimony that the drugs got out  
13:32:41 10 into the community. But how are the plaintiffs going to  
11 produce that evidence?

12 How are you going to produce that in a trial?

13 MR. WEINBERGER: So, Your Honor, we have from  
14 the ARCOS data on the distribution side, what number of  
13:33:07 15 pills were distributed to the pharmacy -- to their own  
16 pharmacies, and how many of those pills ended up getting  
17 dispensed. So we're --

18 COURT REPORTER: This is the court reporter.  
19 I'm assume this is Mr. Weinberger?

13:33:26 20 MR. WEINBERGER: I'm sorry. I'm sorry. Yes.  
21 This is Pete Weinberger.

22 And as it states in our expert reports, we have done  
23 an analysis of that -- of those quantities, and we're using  
24 that analysis then to establish our causation case.

13:33:55 25 And what -- to add on to that -- and, of course, we

1 have experts to testify as to which of those orders  
2 from -- that were filled by their own distribution centers  
3 were suspicious.

4 THE COURT: All right. Have you identified to  
13:34:14 5 the defendants which orders you're going to be relying on  
6 you're claiming are suspicious?

7 MR. WEINBERGER: Yes, we have.

8 THE COURT: Okay. And ballpark we -- you  
9 know, per defendant -- and like per defendant per year, are  
13:34:37 10 we talking about hundreds? Thousands?

11 I mean, I just want to get a sense of what your  
12 experts are going to be saying.

13 MR. WEINBERGER: Pete Weinberger again.

14 I don't have the numbers, I'm sorry, in front of me  
13:34:53 15 right now. But I know that over the relevant time frame,  
16 which would be from 2000- -- where we have data, from 2006  
17 to 2014, which is when these defendants stopped distributing  
18 to themselves, you know, it's certainly into the millions  
19 per defendant.

13:35:18 20 MR. STOFFELMAYR: Judge, it's  
21 Kaspar Stoffelmayr.

22 I can say for Walgreens that plaintiffs' expert  
23 believes that 95 percent of the orders were suspicious.

24 THE COURT: 95 percent of the orders were  
13:35:29 25 suspicious?

1 MR. STOFFELMAYR: 95 percent, yes.

2 THE COURT: Okay.

3 MR. STOFFELMAYR: So it's tens of thousands of  
4 orders easily -- or not millions as Mr. Weinberger says.

13:35:40 5 THE COURT: Okay. All right. So you've got  
6 the ARCOS data, so you know how many were -- you know, that  
7 they were dispensed, they were distributed.

8 Well, then -- I mean, I -- as I said, we're -- the  
9 only way to conduct the Track 1B is if -- is to really --  
13:36:13 10 merely separate distributing from dispensing and have no  
11 testimony about dispensing, because if we have testimony  
12 about dispensing, we're going to have to have discovery on  
13 it, and that's what the defendants clearly argued was not  
14 proper and the Sixth Circuit agreed.

13:36:33 15 So the plaintiffs are not putting in any evidence  
16 about dispensing; is that right?

17 MR. STOFFELMAYR: Judge, may I? -- sorry.  
18 It's Kaspar. May I be heard for one moment on the first --

19 THE COURT: All right.

13:36:50 20 MR. STOFFELMAYR: It is, I think, incorrect.  
21 We will be responding in due course to plaintiffs' Rule 37  
22 motion filed yesterday or the day before.

23 It is not correct that over the course of Track 1 the  
24 defendants collectively or individually ever said that all  
13:37:11 25 dispensing discovery was inappropriate. They never said

1 that to the Sixth Circuit. We have -- and it is unfair to  
2 group defendants on this issue, I think, because different  
3 defendants will take different positions for all sorts of  
4 reasons.

13:37:24 5 But through -- it's a misunderstanding -- and we will  
6 clear this up when we respond to their motion -- but it is a  
7 misunderstanding that we ever took the position that  
8 dispensing, per se, was irrelevant to the Track 1  
9 distribution case and resisted all discovery.

13:37:45 10 Now, I can hear -- you know, my friends are going to  
11 tell me that I'm wrong, but I think that we're entitled to  
12 present that to the Court.

13 THE COURT: Well, you can present it, but  
14 candidly, it's not going to get -- it's not going to get  
13:37:59 15 very far, Mr. Stoffelmayr. You were the ones -- I didn't  
16 want to do the separation, because I didn't think -- I  
17 thought it was intellectually very difficult, practically  
18 very difficult. It's going to get the Court involved  
19 in -- there will be millions of objections to this trial  
13:38:23 20 about whether we're getting into dispensing or not. All  
21 right?

22 The pharmacists chose to ask -- chose to raise this  
23 when you knew very well why I had allowed the plaintiffs to  
24 amend their complaints, and so we had one trial. One trial.  
13:38:41 25 And the jury can examine the totality of what each of these

1 corporations did and whether they contributed to a public  
2 nuisance or not. We don't need to do it over two trials.  
3 But now we've got it split.

4 But I'm not going to let the pharmacies defend with  
13:39:01 5 documents or testimony on dispensing. If we can -- if we  
6 can do a trial on pure distribution, that's what we're going  
7 to have. All right? Because that's what the -- that's what  
8 the defendants wanted apparently. You'll get what you  
9 wanted.

10 So it seems to me we won't have any pharmacists  
11 testifying from either side, because what any pharmacy did  
12 or didn't do on filling prescriptions isn't part of this  
13 case. And the defendants at least believe that their due  
14 diligence, you know -- that's not part of their due  
13:39:47 15 diligence.

16 So the problem is if the plaintiffs think it is -- if  
17 the plaintiffs think it is, then we're getting into  
18 dispensing. Because if the plaintiffs think it is, then  
19 defendants are going to say we want the defend the case the  
13:40:01 20 plaintiffs are bringing.

21 And then we get into testimony about dispensing  
22 practices at given pharmacies and the defendants will need  
23 to call the pharmacists who were there, and then the  
24 plaintiffs are going to say, Well, we want to have the  
13:40:21 25 dispensing records of at least those pharmacies -- or those

1 pharmacists for the time that they were pharmacists at those  
2 stores so we can cross-examine them, and there we go going  
3 right back into, you know, the mess we -- the mess that  
4 we've got. And then the Track 1B goes back into a  
13:40:47 5 dispensing trial.

6 So I'm -- I -- you know, you all have sort of created  
7 this mess. I mean, again, the plaintiffs chose to separate,  
8 you know, distribution claims from dispensing claims way  
9 back with the pharmacies, and I never really  
13:41:08 10 understood -- and I understand the words, but I was  
11 concerned whether it could be done, and I am no more  
12 comfortable with it now two years down the road.

13 And so I'm not really interested in dealing with a lot  
14 of motions on it, and I'm certainly -- this trial can't  
13:41:31 15 function if every question is subject to an objection, and  
16 now you're getting into dispensing.

17 So, again, it seems to me we could have a trial purely  
18 on the historic record, and we literally need no witnesses.  
19 You know, the documents are what they are, and the  
13:41:56 20 plaintiffs can say, all right, these orders were suspicious.  
21 Then the defendants should have done X, Y, and Z.

22 And the defendants can attack on a number of bases.  
23 They can say, Well, guess what? Most of these weren't  
24 suspicious at all, you know, so there was nothing we needed  
13:42:14 25 to do, or if it was suspicious, here's what we did, and this

1 was reasonable, and here are the documents to show what we  
2 did, and then you'd make your arguments.

3 So I -- we could -- we could -- we could have a trial  
4 like that, and then no one is going to call the pharmacists  
13:42:32 5 from individual stores to testify what -- you know, what did  
6 or didn't happen at those pharmacies, because it's not those  
7 pharmacists who were doing the due diligence.

8 So how does that sound for a trial? The plaintiffs'  
9 side and the defendants' side?

13:42:58 10 MR. WEINBERGER: Your Honor, this is  
11 Pete Weinberger.

12 We are prepared to try the case using those  
13 parameters.

14 MR. STOFFELMAYR: I'm sorry.  
13:43:09 15 Kaspar Stoffelmayr speaking through the defendants.

16 It is so for me personally impossible to understand  
17 how the plaintiffs can prove their case with those  
18 parameters. Maybe I'm not imaginative enough or I just  
19 don't understand how they connect the dots.

13:43:31 20 But it sounds to me that if plaintiffs (inaudible)  
21 actually put their case in that way, the case is over  
22 before --

23 COURT REPORTER: Mr. Stoffelmayr.  
24 Mr. Stoffelmayr, can you say that again. We're getting  
13:43:52 25 really bad static here.

1 MR. STOFFELMAYR: Yeah. I can hear the  
2 clicking, too. I'm not sure -- I'm not sure what that is.  
3 I apologize if it's something at our end.

4 Well, what I was trying to say is, I don't understand  
13:44:04 5 how plaintiffs can prove their case that way, and what we  
6 would want to do for a defense case, and what we would want  
7 to do -- see what the Court really allows us to do -- would  
8 obviously depend on what the plaintiffs' case actually looks  
9 like. If their case is actually a stack of documents and  
13:44:25 10 that's it, our case would look very different than if -- if  
11 it's something else -- if it's something beyond that.

12 THE COURT: They've got a stack of documents  
13 and a bunch of experts.

14 MR. STOFFELMAYR: If what you're asking me,  
13:44:41 15 Judge, is do we consent to a trial without any live  
16 witnesses who work in -- at pharmacies in Cuyahoga and  
17 Summit Counties? The answer is obviously no. We don't  
18 consent to that. But I don't think that's what you were  
19 asking for.

13:44:56 20 THE COURT: Well, I'm not going to -- I'm --  
21 the point is, I'm not going to let any of those people  
22 discuss any dispensing practices they did, and the point is,  
23 their testimony may -- as I see it, I don't know what  
24 relevant testimony they have unless there's -- I mean, if  
13:45:17 25 there's a document that says, all right, you know, on



1 March 3rd, 2012, someone from Walmart corporate called  
2 Walmart pharmacy on 55th and Euclid, all right, and there's  
3 an issue as to whether that really happened, well, the  
4 person who got the call can certainly testify, Yeah, they  
13:45:45 5 did call me. All right? Okay? Fine.

6 But to talk about -- other than that, there would be  
7 no -- nothing relevant for that pharmacist to say. The  
8 pharmacist isn't doing the due diligence. Someone at  
9 corporate. And it would not be at all relevant or proper  
13:46:05 10 for the pharmacist to talk about any dispensing practices at  
11 that pharmacy. I wouldn't -- I wouldn't permit it, because  
12 the pharmacies have gotten the Sixth Circuit to truncate the  
13 case. So you can't put it back in.

14 MR. DELINSKY: Your Honor, this is  
13:46:26 15 Eric Delinsky on behalf of CVS.

16 THE COURT: Yes.

17 MR. DELINSKY: There's -- there are other  
18 issues that pharmacists should be able to testify on. The  
19 plaintiffs' case is that pharmacies place suspicious orders  
13:46:49 20 to distribution centers. The pharmacies are part of the  
21 transaction, the ordering transaction, that comprises  
22 plaintiffs' case. It --

23 THE COURT: All right. Mr. Delinsky, what  
24 is -- all right. You call a pharmacist, describe -- say,  
13:47:13 25 all right, to explain how he or she places orders?

1 MR. DELINSKY: Correct.

2 THE COURT: Well, what are they going to say?

3 How does a pharmacist place an order?

4 MR. DELINSKY: They are going to -- they -- a  
13:47:33 5 pharmacist could talk about what they take into account in  
6 the course of placing an order or approving an order or  
7 adjusting an order.

8 THE COURT: Yeah. Well, that's my concern. I  
9 don't -- the pharmacist is going to say, Well, I take into  
13:47:55 10 account the number of prescriptions I expect to receive.

11 Isn't that one of the main things they take into  
12 account?

13 Hello?

14 MR. DELINSKY: Your Honor, I don't think the  
13:48:11 15 testimony necessarily would come in that way. They -- a lot  
16 of what they take into account is what's on the shelves and  
17 what's not on the shelves, what they think they may need.

18 THE COURT: Well, but how --

19 MR. DELINSKY: And that's more --

13:48:31 20 THE COURT: The only thing that -- the only  
21 reason they would need it, Mr. Delinsky, is if they  
22 anticipated demand, and the demand certainly isn't black  
23 market or theft, the demand would be people coming in with  
24 prescriptions for that drug, right?

13:48:53 25 MR. DELINSKY: Even if the testimony went that

1 far, Your Honor, much of this could be controlled in terms  
2 of what questions are allowed and what questions are not  
3 allowed.

4 THE COURT: Yeah. Well, I'm not -- that's  
13:49:05 5 what we're not going to have. We're not going to have. You  
6 all got the Sixth Circuit to truncate this case, and so be  
7 it. It will be truncated.

8 Plaintiffs aren't going to put in any testimony about  
9 the dispensing practices at all and I'm not going to allow  
13:49:21 10 any testimony about dispensing or reference to dispensing,  
11 because the moment that pharmacist says, you know, I've got  
12 to fill the shelves, I anticipate I -- you know, got a  
13 thousand prescriptions in February, I'm anticipating at  
14 least a thousand in March, well, that begs the question of  
13:49:43 15 whether, you know, they were lawful, suspicious, whatever,  
16 and the plaintiffs are going to want to have their records  
17 to cross-examine that pharmacist. And then we're back into  
18 the dispensing practices of particular pharmacists, and I'm  
19 not --

13:50:01 20 MR. DELINSKY: Your Honor -- I apologize,  
21 Your Honor.

22 THE COURT: So --

23 MR. DELINSKY: I fear there's an apples and  
24 oranges problem.

13:50:09 25 The Sixth Circuit litigation pertains to substantive

1 causes of action and claims seeking to impose.

2 COURT REPORTER: Can you repeat that? It is  
3 hard to hear.

4 MR. DELINSKY: The Sixth Circuit litigation  
13:50:26 5 was focused on requests for relief based on dispensing, and  
6 the Sixth Circuit determined, as we know, that those claims  
7 can't lie in Track 1.

8 That is a different question of admissibility in a  
9 distribution case. That is not an issue that the  
13:50:53 10 Sixth Circuit was asked to rule on or that the Sixth Circuit  
11 did rule on, and the effect of the ruling -- the evidence  
12 limitation that you are proposing, Your Honor, would be to  
13 go back in time -- to go back to Track 1A and find out of  
14 the Track 1A distribution records, the dispensing evidence  
13:51:24 15 that was permitted, and, in fact, that was ordered.

16 And our position is is that the Track 1 trial could  
17 proceed with the record established in the Track 1A case.  
18 It has a certain component of dispensing in it, and we do  
19 not believe it would be appropriate to go back and excise  
13:51:57 20 that from the case.

21 THE COURT: All right. Look. All right.  
22 Look. This is what I'm going to rule. I'm going to make it  
23 very simple.

24 I'm not going to tell the pharmacists [sic] they can't  
13:52:07 25 call pharmacists to testify. But I am ruling this way.

1 If you call a pharmacist, you must have produced well  
2 in advance of trial the dispensing records of that pharmacy  
3 of prescription opioids for the period that that pharmacist  
4 was the pharmacist. All right?

13:52:32 5 So if you've got a pharmacist who is there since 2010,  
6 you've got to produce the dispensing records of that  
7 pharmacy from 2010 to 2014. All right? So you know who you  
8 want to call. They've been identified and you produce those  
9 records so the plaintiff has them for cross-examination.

13:53:00 10 And then they may or may not need them for cross-examination  
11 depending on what the witness says.

12 But they'll be ready if they need to.

13 So I think that's the simplest way to do it.

14 SPECIAL MASTER COHEN: Judge, this is David.

13:53:19 15 May I ask --

16 THE COURT: Everyone is clear on that?

17 Everyone is clear on that?

18 Yes, who had a question?

19 SPECIAL MASTER COHEN: I'm sorry, Judge. This  
13:53:25 20 is David. I just had a clarification question.

21 I believe that three of the defendants stated that  
22 they would -- that they did intend to call pharmacists, and  
23 many of those pharmacists, of course, were listed in witness  
24 lists, but they were not deposed.

13:53:44 25 And so my question simply is, do you have a ruling now

1 or do you want to think about it with regard to whether  
2 those pharmacists, if the defendants still want to call them  
3 and after the data is produced, you would allow deposition  
4 or not?

13:54:00 5 THE COURT: We'll cross that bridge when I  
6 come to it. If someone feels they need to depose someone  
7 that was previously identified and not deposed, they'll have  
8 to make a case for it.

9 SPECIAL MASTER COHEN: Thank you, Judge.

13:54:16 10 THE COURT: So any pharmacist --

11 COURT REPORTER: I'm sorry. Who was --

12 THE COURT: -- any pharmacist who is  
13 testifying, you've got to produce those dispensing records  
14 for the period that pharmacist was at that store.

13:54:29 15 SPECIAL MASTER COHEN: And I just want to say,  
16 this is David Cohen for the court reporter. Excuse me for  
17 not identifying myself earlier.

18 THE COURT: So it may be this trial will go a  
19 lot faster than four weeks.

13:54:47 20 Okay. And, again, I think that -- I think that, you  
21 know, it's -- again, I didn't want to have two trials, but  
22 that's what we've got. So that will be the November trial,  
23 and the May trial will be everything.

24 There were one or two questions I had on the status  
13:55:41 25 report. I didn't see any reference to West Virginia -- the

1 case that was remanded to the federal court in West Virginia  
2 involving the distributors, and that case is there. I know  
3 it's moving forward.

4 MR. WEINBERGER: Your Honor, this is  
13:55:59 5 Pete Weinberger. I'm going to -- I think Paul Farrell is on  
6 the phone. He can address where things stand on CT2 with  
7 respect to the distributor case.

8 The reason that we didn't include it in the status  
9 report is that generally the status report relates to, you  
13:56:21 10 know, the Track 1B and now the three cases, and I don't  
11 believe -- well, it's quite possible there are attendees  
12 from the three distributors on this call.

13 THE COURT: Oh, I see.

14 MR. WEINBERGER: But perhaps not. But if you  
13:56:44 15 want Paul Farrell to address where we are before --

16 THE COURT: No. I see you only -- it's number  
17 5. It updates on remanded cases, including any Track 1B  
18 defendants, and that case only involves a distributor. So,  
19 okay. I see why it was omitted.

13:57:04 20 Everyone should know it's still there. It's still  
21 active. That's all. I don't want anyone to think that it  
22 wasn't.

23 MR. FARRELL: Judge, this is Paul Farrell.

24 It is still there and it is still active.

13:57:18 25 THE COURT: Oh, I know that. I just didn't

1 want anyone to think that it wasn't because it's not on the  
2 report and I see why it's not.

3 All right. Well, I think there was -- I guess there  
4 was some issue we were holding off issuing the final  
13:57:47 5 schedule for the Track 1B in November.

6 I can't -- I don't recall what -- there's some issue  
7 between the parties who were still -- they were still  
8 disagreeing over. I can't -- we had held off doing it.

9 Does anyone recall what --

13:58:09 10 MS. SWIFT: Judge, this is Kate Swift on  
11 behalf of Walgreens.

12 We -- and when I say we, I mean, both defendants and  
13 plaintiffs -- submitted to Special Master Cohen on May 20th  
14 a proposed list of dates that we have agreed upon for the  
13:58:28 15 remainder of the Track 1B schedule. I think that is where  
16 that stands.

17 THE COURT: All right. Well, we'll get one  
18 out. Now that we've clarified things, we'll get that order  
19 out.

13:58:48 20 Now, of course, our federal court, and to my  
21 knowledge, you know, every federal court in the country, no  
22 one has had any jury trial since the middle of March.

23 We have -- our court meets every few weeks to take  
24 pulse of things. We've determined we will not resume jury  
13:59:15 25 trials before August. We haven't said we'll definitely do



1       them in August. They won't be before August. We're meeting  
2       Friday the June the 12th to assess things and to supplement  
3       our orders.

13:59:35 4               I looked at the schedule for Track 1A, and I believe  
5       that's about three months before that trial. So sometime in  
6       the mid to late August, which was several months before the  
7       trial, we sent out an inquiry to several hundred jurors  
8       inquiring whether they would be able to sit for a one-month  
9       trial.

14:00:01 10              And then we got -- the ones who said they could, then  
11       we sent them the detailed questionnaire. Then we went  
12       through that process. I would do the same process. It  
13       worked very well. The point is, that's -- for a November  
14       trial, that would mean sending those inquiries out in  
14:00:24 15       August.

16              You know, no one knows how people are going to feel  
17       about sitting on a jury, and we can take all the precautions  
18       we want in court to try and keep people safe, but if jurors  
19       don't feel they'll be safe, they'll ask to be excused or  
14:00:45 20       they won't come or really won't want to come.

21              No one is contemplating arresting people to be jurors.  
22       I'm not being facetious. No one would do that. But no one  
23       wants a jury composed of people who are so fearful that they  
24       can't concentrate on the testimony.

14:01:06 25              So it remains to be seen what we can do. I'm

1 guardedly optimistic, but no one knows exactly how -- you  
2 know, the course of this pandemic or how people are going to  
3 feel. So that's the reality. But we'll keep going as we  
4 can.

14:01:30 5 So we'll get the schedule out and then everyone should  
6 work on getting the Track 3 schedule back with the one  
7 revision. I want the trial to start on -- opening  
8 statements on May the 10th. So that's when it will begin.

9 All right. Was there anything that anyone else wanted  
14:01:57 10 to bring up? I think I've covered the things I wanted to  
11 cover, and I've done most -- I have asked my questions and  
12 done most of the talking, but there may be some other things  
13 that I've left out.

14 MR. STOFFELMAYR: Judge, it's  
14:02:10 15 Kaspar Stoffelmayer again, if I could just ask one question.

16 THE COURT: Sure.

17 MR. STOFFELMAYR: You asked us maybe a month  
18 ago now to meet and confer with the Ohio Board of  
19 Pharmacy --

14:02:19 20 THE COURT: Oh, right.

21 MR. STOFFELMAYR: -- about writing something  
22 to the Sixth Circuit. We have discussed this with their  
23 outside counsel. But I just want to let you know we have  
24 been pursuing, discussed it with their outside counsel,  
14:02:36 25 explained the situation and also what's going on between the

1 Track 2 cases -- sorry -- Track 1B cases --

2 THE COURT: Right.

3 MR. STOFFELMAYR: -- Track 3 cases.

4 They told us they needed to confer with their client.

14:02:47 5 That was a couple of weeks ago. We haven't heard back. I  
6 just wanted to make sure you were aware that, A, that has  
7 not happened yet.

8 THE COURT: All right.

9 MR. STOFFELMAYR: But not that we have been  
14:02:57 10 ignoring your request.

11 THE COURT: Well, I'm making a suggestion that  
12 it is -- the specific issue that is -- that is the subject  
13 of the mandamus doesn't exist anymore the way it was set up  
14 because that has been mooted by the earlier order.

14:03:23 15 But the same -- the same issue is going to arise very  
16 shortly in Track 3 because the defendants will want the  
17 exact same records from the Ohio Board of Pharmacy that they  
18 would have wanted for Track 2 when it included dispensing  
19 claims.

14:03:45 20 Am I correct?

21 MR. STOFFELMAYR: Yes. We agree.

22 THE COURT: All right. So -- but because  
23 judges are very careful and they don't want to decide things  
24 that are moot, they need to -- someone has to advise the  
14:03:59 25 Court of that, okay, that those records are not -- not

1 needed for the November trial, but they are going to be --  
2 they are going to be needed for the May 2021 trial. And the  
3 issue is the same. They're the same records. And  
4 presumably the Ohio Board of Pharmacy will have exactly the  
14:04:25 5 same objections.

6 But I think you need -- you've got to -- I mean, the  
7 parties won't do it. You know, I -- someone should do that.

8 Now, I haven't received any inquiry from the  
9 Sixth Circuit anything about that. I haven't seen that  
14:04:45 10 they've set a briefing schedule. They haven't asked me to  
11 make a response if I wish. And I haven't -- I've received  
12 no notification.

13 So I'm just strongly suggesting you meet with the --  
14 you know, and tell them this is what -- this is what I think  
14:05:06 15 should be done. And maybe the Court will just say, Okay.  
16 We'll address it in this way, or we've got to wait until,  
17 you know, there's a new objection and you've got to  
18 promulgate the same -- the same third-party subpoena,  
19 whatever, in Track 3. I don't know. They'll tell  
14:05:26 20 you -- you'll get some directive.

21 But whatever ruling would be the same. It's the same  
22 document for the same purpose.

23 All right. Or maybe that -- maybe the simplest thing  
24 is for me to do it. I don't know. I mean, I didn't  
14:05:45 25 initiate the mandate.

1 I mean, certainly if they ask me -- if they ask me for  
2 a response, that's what I would include. But I think it's  
3 more appropriate for the parties to advise the Court.

4 Okay. Was there anything else?

14:06:08 5 MR. RICE: Judge.

6 THE COURT: Yes.

7 MR. RICE: This is Joe Rice. This is  
8 Joe Rice.

9 We've got some -- in the status report it talks about  
14:06:13 10 some motions that have been pending for quite a while of a  
11 general nature. I'm just trying to get some insight.

12 THE COURT: Well, all right.

13 Well, the oldest is that common benefits fund. I have  
14 not forgotten about that, Joe, and I -- that's still on the  
14:06:43 15 Court's attention. I have not at all forgotten about that  
16 and I'll be turning to that.

17 I think the other things I've pretty much dealt with  
18 other than the --

19 MR. RICE: Joe Rice again.

14:07:03 20 It was the common benefit thing that I was addressing.

21 THE COURT: All right. Thank you.

22 That's the oldest one on the status report. The Court  
23 has not forgotten about it. I'll be turning to that  
24 shortly.

14:07:17 25 The one that is -- that I'll need to rule on is

1 probably the last one. May 24th the plaintiffs filed a  
2 motion to propound nationwide dispensing data. So the  
3 defendants will be responding to that.

14:07:42

4 I think the other things, you know, are the other  
5 things I dealt with through my rulings today.

6 Okay. Anything else?

14:08:16

7 The last thing, I guess, I do want to -- I think it's  
8 a good idea to have one of these conferences once a month,  
9 and I think I'm suggesting maybe Thursday, June 25th, the  
10 last Thursday in June. I guess we could do it at -- we  
11 could do it at 1:00 on Thursday, June 25th.

14:08:58

12 And we can have the same call instructions. And then,  
13 I guess, if I get a status report two days before, which  
14 would be, say, noon on Tuesday the 23rd. I think these are  
15 useful to keep both of these cases on track and deal with  
16 things that come up.

14:09:16

17 So we'll keep that practice going, and at some point  
18 we may be able to meet in person, but candidly, given that  
19 everyone is all over the country, we save a whole lot of  
20 time and money by doing it this way, and I'm comfortable  
21 doing it by phone, except this -- someone has this very bad  
22 clicking that made it hard for all of us, particularly our  
23 court reporter. So hopefully we can figure out what that  
24 was.

14:09:32

25 Okay. Thank you, everyone, and I hope you and your

1 families continue to stay safe.

2 And with that, we're adjourned.

3 COUNSEL EN MASSE: Thank you, Judge.

4 - - -

5 (Proceedings concluded at 2:09 p.m.)

6

7 C E R T I F I C A T E

8

9 I certify that the foregoing is a correct transcript  
10 from the record of proceedings in the above-entitled matter.

11

12 /s/ Donnalee Cotone 28th of May, 2020  
13 DONNALEE COTONE, RMR, CRR, CRC DATE  
14 Realtime Systems Administrator

15

16

17

18

19

20

21

22

23

24

25